The HCPLive spondyloarthritis page is a resource for medical news and expert insights on spondylitis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for autoimmune disease, and more.
May 6th 2024
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.
Scientists Identify Mechanism of Action of Potential Psoriasis Therapy
March 12th 2015Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.
Researchers Identify Potential Protein Triggers of Psoriasis
February 20th 2015Researchers have reportedly identified several proteins that are highly prevalent in human psoriasis and may play an important role in the development and progression of the disease and its co-morbidities and complications, including psoriatic arthritis.
Secukinumab Effective for Treatment-Resistant Ankylosing Spondylitis
November 18th 2014A Phase 3 trial of the monoclonal antibody secukinumab indicates it is an effective treatment for patients with ankylosing spondylitis (AS) incompletely treated by standard therapy, according to data presented at the 2014 American College of Rheumatology meeting.
Patients with Psoriatic Arthritis Tend to Quickly Modify or Abandon Initial Treatment
October 2nd 2014The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.
Oral Medication Option May Lead to Improved Treatment Adherence in Patients with Psoriatic Arthritis
September 4th 2014Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Apremilast and the Future of Psoriatic Arthritis Treatment
August 21st 2014When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.
The National Psoriasis Foundation Announces Ambitious New Programs and Initiatives
August 21st 2014The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.
Targeting Inflammation in Diabetes through Disease-modifying Therapies
July 8th 2014An endocrinologist from the University Hospital Basel in Switzerland discusses the role of inflammation in the pathogenesis of type 2 diabetes, outlining the reasons why clinicians should target inflammation when treating diabetics.
Weight Loss Improves Disease Management in Patients with Psoriatic Arthritis
July 1st 2014Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.
Cardiovascular Risk Factors Associated with Psoriatic Arthritis Complicate Treatment Decisions
May 28th 2014Patients with psoriatic arthritis may be at increased risk for cardiovascular disease, so physicians must carefully weigh the pros and cons of treatment with corticosteroids and other proatherogenic drugs.